You may not like ingesting Big Pharma’s products or buying into their trillion-dollar business, but their dirty insider trading can still make you money.
High-up executives in big-name drug brands buy and sell stocks at their leisure.
Only a fool would believe they’re not doing this because they know something you don’t.
Let me show you how shareholders in this stock (a.k.a. future YOU) can make $58,320 thanks to two big insider sales.
There’s a reason insider trading is called that.
People behind the scenes in the stock market or companies try to profit from news or changes that haven’t gone public yet.
Sure, it’s illegal, but that doesn’t stop them…
But don’t worry. YOUR profits from these trades are 100% legal.
My research focuses on when tons of shares are changing hands. Especially when those hands belong to executives or partial owners of the company.
Big Pharma in all of its vices dabbles in insider trading just like every other crooked company.
I found a recent sale in Quidel Corporation (QDEL) amounting to $2,188,659.
And this huge unloading of stocks to cash can be attributed to two heavyweight insiders within the span of 8 days.
QDEL’s President/CEO and Senior Vice President of Global Commercial Operations sold 311,040 shares between June 18 and June 26.
This comes with the announcement just days ago that QDEL received FDA approval for its newest form of drug test.
Aimed at hospitals and private practices, this product is meant for medical professionals’ convenience.
This test collects a patient’s urine and can be evaluated for dozens of drug classes.
It may come as a relief to criminal investigators and suspicious employers, but for QDEL investors, it’s a bittersweet announcement.
You’re probably thinking that QDEL’s executives were wrong to sell at this point, seeing as this breakthrough should be good news for the company.
Actually, both insiders have been stealthily unloading shares since this time last year!
But don’t worry. If you had bought into QDEL in August of 2016, just two years later you’d realize a $58,320 profit.
With the news of their latest FDA approval, QDEL is looking at reaching its August 2018 highs again.
And with the price inching closer and closer to its average across 200 days, a rally is sure to follow.
Make sure you’re riding that rally to the top, and Big Pharma’s dirty dealings can actually benefit you for once.
